Metal–Organic Frameworks@Au Nanoreactor as an Oxidative Stress Amplifier for Enhanced Tumor Photodynamic Therapy through the Alleviation of Hypoxemia and the Depletion of Glutathione

Recently, photodynamic therapy (PDT) based on the generation of cytotoxic reactive oxygen species (ROS) has drawn great attention in tumor treatment. However, the hypoxia tumor microenvironment (TME) inhibits the generation efficacy of ROS, and the high glutathione (GSH) level in TME could neutraliz...

Full description

Saved in:
Bibliographic Details
Published inACS applied bio materials Vol. 6; no. 9; pp. 3376 - 3386
Main Authors Wang, Haoran, Chen, Tiejin, Ren, Haohui, Liu, Weimin, Nan, Fuchun, Ge, Jiechao, Wang, Pengfei
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 18.09.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Recently, photodynamic therapy (PDT) based on the generation of cytotoxic reactive oxygen species (ROS) has drawn great attention in tumor treatment. However, the hypoxia tumor microenvironment (TME) inhibits the generation efficacy of ROS, and the high glutathione (GSH) level in TME could neutralize the generated ROS, both of which strongly reduce the therapeutic efficiency of PDT. In this work, we first constructed the porphyrinic metal–organic framework PCN-224. Then Au nanoparticles were decorated on the PCN-224 to obtain the PCN-224@Au. The decorated Au nanoparticles could not only produce O2 through the decomposition of H2O2 in tumor sites for enhancing the generation of 1O2 in PDT but also deplete glutathione through the strong interactions between Au and sulfhydryl groups on glutathione to weaken the antioxidant ability of tumor cells, thus amplifying the 1O2 damage to cancer cells. The in vitro and in vivo experiments totally exhibited that the as-prepared PCN-224@Au nanoreactor can be used as an oxidative stress amplifier for enhanced PDT, which provides a promising candidate to conquer the limitation of intratumor hypoxia and high GSH level on PDT of cancer.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2576-6422
2576-6422
DOI:10.1021/acsabm.2c01090